Suppr超能文献

1例对第4次静脉注射免疫球蛋白治疗有反应的川崎病合并冠状动脉瘤病例

A Case of Kawasaki Disease with Coronary Aneurysm Responding to the 4th IVIG Treatment.

作者信息

Kim Ju Young, Kim Hyun Jung

机构信息

Department of Pediatrics, Eulji University Hospital, Eulji University School of Medicine, 1306, Dunsan-dong, Seo-gu, Daejeon 302-799, Republic of Korea.

出版信息

Case Rep Cardiol. 2014;2014:821812. doi: 10.1155/2014/821812. Epub 2014 Aug 5.

Abstract

Kawasaki disease is an acute febrile illness that usually occurs in children younger than 5 years of age. The use of intravenous immunoglobulin (IVIG) within the first 10 days of illness has been shown to reduce the incidence of coronary artery aneurysms significantly. The relative roles of repeated doses of intravenous immunoglobulin (IVIG) are controversial in refractory Kawasaki disease (KD). Most experts recommend the second retreatment with IVIG, 2 g/kg in refractory KD. However, the dose-response effect of the third or fourth IVIG was uncertain. Although there have been a significant number of reports on new therapeutic options for refractory KD, such as steroid, infliximab, methotrexate, and other immunosuppressants, their effectiveness in reducing the prevalence of coronary artery aneurysms was unproven. We present here KD patient with small coronary artery aneurysm who is resistant to the third IVIG and steroid pulse therapy but showed improvement immediately after the infusion of the 4th IVIG on fever day 18.

摘要

川崎病是一种急性发热性疾病,通常发生在5岁以下儿童。已证明在发病后10天内使用静脉注射免疫球蛋白(IVIG)可显著降低冠状动脉瘤的发生率。在难治性川崎病(KD)中,重复剂量静脉注射免疫球蛋白(IVIG)的相对作用存在争议。大多数专家建议在难治性KD中第二次使用IVIG进行再治疗,剂量为2 g/kg。然而,第三次或第四次IVIG的剂量反应效果尚不确定。尽管有大量关于难治性KD新治疗选择的报道,如类固醇、英夫利昔单抗、甲氨蝶呤和其他免疫抑制剂,但它们在降低冠状动脉瘤患病率方面的有效性尚未得到证实。我们在此报告一例患有小冠状动脉瘤的KD患者,该患者对第三次IVIG和类固醇脉冲疗法耐药,但在发热第18天输注第四次IVIG后立即出现改善。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ec3/4137746/f6446bb612cf/CRIC2014-821812.001.jpg

相似文献

1
A Case of Kawasaki Disease with Coronary Aneurysm Responding to the 4th IVIG Treatment.
Case Rep Cardiol. 2014;2014:821812. doi: 10.1155/2014/821812. Epub 2014 Aug 5.
2
Kawasaki disease: a comprehensive review of treatment options.
J Clin Pharm Ther. 2015 Dec;40(6):620-5. doi: 10.1111/jcpt.12334. Epub 2015 Nov 7.
3
Clinical outcome of patients with refractory Kawasaki disease based on treatment modalities.
Korean J Pediatr. 2016 Aug;59(8):328-34. doi: 10.3345/kjp.2016.59.8.328. Epub 2016 Aug 24.
5
Kawasaki disease in Sicily: clinical description and markers of disease severity.
Ital J Pediatr. 2016 Nov 2;42(1):92. doi: 10.1186/s13052-016-0306-z.
6
Outcomes of Kawasaki Disease Children With Spontaneous Defervescence Within 10 Days.
Front Pediatr. 2019 Apr 24;7:158. doi: 10.3389/fped.2019.00158. eCollection 2019.
7
A case of intravenous immunoglobulin-resistant Kawasaki disease treated with methotrexate.
Yonsei Med J. 2002 Aug;43(4):527-32. doi: 10.3349/ymj.2002.43.4.527.
8
9
Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Pediatrics. 2004 Dec;114(6):e689-93. doi: 10.1542/peds.2004-1037. Epub 2004 Nov 15.

本文引用的文献

1
Steroid pulse therapy for children with intravenous immunoglobulin therapy-resistant Kawasaki disease: a prospective study.
Pediatr Cardiol. 2013 Apr;34(4):959-63. doi: 10.1007/s00246-012-0589-9. Epub 2012 Nov 27.
3
Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006.
Pediatrics. 2009 Jul;124(1):1-8. doi: 10.1542/peds.2008-0730.
5
Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.
J Pediatr. 2008 Dec;153(6):833-8. doi: 10.1016/j.jpeds.2008.06.011. Epub 2008 Jul 30.
6
Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.
J Pediatr. 2006 Aug;149(2):237-40. doi: 10.1016/j.jpeds.2006.03.050.
7
Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin.
Circulation. 2005 Sep 27;112(13):2031-9. doi: 10.1161/CIRCULATIONAHA.105.546150. Epub 2005 Sep 19.
9
Case-control study of giant coronary aneurysms due to Kawasaki disease.
Pediatr Int. 2003 Aug;45(4):410-3. doi: 10.1046/j.1442-200x.2003.01744.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验